Noticeable, within the same group of RCCs staged pT3/4, a further timely difference in RFS between CXCR3high and CXCR3low expression has become apparent (median 16 vs. 24.5 months), Figure 9A. The same trend was observed when focusing on tumor grade, G1/2 tumors have still no reached RFS, irrespective of their CXCR3 status. The gene discussed is CXCR3; the disease is neoplasm.